Company Overview
| Stock Name | NT Pharma |
|---|---|
| Stock Code | 01011 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們是中國最大的全面綜合疫苗供應鏈及推廣和銷售服務供應商,亦是國內第二大的第三方藥品推廣和銷售服務供應商。業務包括供應鏈服務(清關、倉儲、交付、開具發票、收繳應收款項等)及推廣和銷售服務(向醫療從業人員介紹臨床用途、組織研討會等)。 |
| Listing Date | 2011-04-20 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 香港干諾道中168-200號信德中心西座21樓2102室 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | ntpharma.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 4.54 / shares |
| Offer Price Range | To be extracted |
| Lot Size | 500 shares |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | 2011-04-08 to 2011-04-13 |
| Global Offering Shares | 357,032,000 shares |
| HK Public Offer Shares (Initial) | 35,703,500 shares (10.0%) |
| Public Offer Lots (Initial) | 71,407lots (Pool A35,703lots,Pool B35,704lots) |
| International Placing Shares (Initial) | 321,328,500 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 1,081,916,500 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | No cornerstone investors |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 1,620,925,280 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| HK Market Cap | HK$ 855.7M |
| Est. Threshold | HK$ 9.37B |
| Analysis Result | HK market cap below threshold, need +995% |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利約人民幣129.4百萬元 |
| Period-End Cash Balance | 人民幣154.9百萬元 |
| Listing Expenses | ~HK$ 187,100,000 |
| Listing Expenses / Funds Raised | ~11.54% |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2008 | 2009 | 2010 |
|---|---|---|---|
| Revenue | 1,413,985 | 2,395,038 | 2,667,978 |
| Cost of sales | -1,178,904 | -1,915,167 | -2,004,775 |
| Gross profit | 235,081 | 479,871 | 663,203 |
| Other income and gains, net | 48,196 | 7,670 | 28,698 |
| Selling and distribution expenses | -108,129 | -237,418 | -354,456 |
| Administrative expenses | -43,147 | -55,999 | -90,056 |
| Operating profit | 87,690 | 192,385 | 255,537 |
| Net finance costs | -14,277 | -17,128 | -45,379 |
| Profit before tax | 73,413 | 175,257 | 210,158 |
| Income tax expense | -20,150 | -58,087 | -80,748 |
| Profit for the year | 53,263 | 117,170 | 129,410 |
| Profit attributable to owners | 53,263 | 117,170 | 128,610 |
Balance Sheet
| Item | 2008 | 2009 | 2010 |
|---|---|---|---|
| Cash and cash equivalents | 67,803 | 212,240 | 154,913 |
| Trade and bills receivables | 575,514 | 1,213,754 | 1,738,213 |
| Inventories | 125,690 | 231,016 | 527,054 |
| Total current assets | 820,269 | 1,713,000 | 2,467,260 |
| Total assets | 979,066 | 1,947,188 | 2,755,336 |
| Total current liabilities | 762,508 | 1,608,307 | 2,250,398 |
| Total liabilities | 763,390 | 1,610,312 | 2,253,059 |
| Total equity | 215,676 | 336,876 | 502,277 |
| Equity attributable to owners | 200,546 | 321,746 | 487,147 |
| Interest-bearing borrowings | 186,497 | 510,719 | 840,187 |
Cash Flow Statement
| Item | 2008 | 2009 | 2010 |
|---|---|---|---|
| Net cash from operating activities | -37,699 | -251,274 | -383,235 |
| Net cash from investing activities | -66,845 | -63,019 | -57,599 |
| Net cash from financing activities | 108,201 | 459,611 | 378,104 |
| Net increase in cash | 3,657 | 145,318 | -62,730 |
| Depreciation of PP&E | 6,096 | 4,864 | 12,671 |
| Depreciation of right-of-use assets | 324 | 324 | 360 |
| Amortisation of intangible assets | 4,595 | 4,117 | 4,393 |
| Purchase of PP&E | -72,055 | -63,619 | -51,167 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 3.82 |
|---|---|
| First Day Open | HK$ 4.2 |
| First Day Change | -15.86% |
| First Day Volume | 130166000.0 |
| First Day Turnover | 525403000.0 |
| Use of Proceeds | 1、約25%或267.6百萬港元,將主要用于透過自然發 展及合并與收購的方式擴展及提升我們的分銷網絡(以疫苗業務為主)。 ;
2、約25%或267.6百萬港元,將用于提升及擴展我們的基礎設施;
3、約10%或107.1百萬港元,將用作擴充我們的疫苗及藥品推廣團隊;
4、約20%或214.0百萬港元,將用作透過取得其他疫苗及藥品分銷及/或推廣權特許權擴展我們產品的投資組合;
5、約20%或214.0百萬港元,將用于向知名的海外供應商采購進口疫苗或藥品。 |
Underwriting Syndicate
Sole Sponsor (1)
UBS Securities Hong Kong Limited CE BIN466
Overall Coordinators (1)
UBS Securities Hong Kong Limited CE BIN466
Joint Bookrunners (2)
Joint Lead Managers (2)
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 吳鐵 | — |
| Company Secretary | 吳育強 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 緊隨全球發售後(假設超額配股權未獲行使),Golden Base持有46.68%,TPG Star持有13.55%,TPG Biotech持有6.77%;吳鐵先生及錢余女士各自持有Golden Base 50%權益,被視為控股股東。 |
|---|




